Mycophenolic Acid Level (Southeast Michigan Only)
Mycophenolate Mofetil, Cellcept TM, Myfortic TM
Test Codes
EPIC: LAB1231314, Beaker: MPA, Antrim: 32009
Department
Toxicology
Specimen Collection Criteria
Collect (preferred specimens): One plain Red-top tube. (Minimum Whole Blood: 2.0 mL)
Also acceptable: One Lavender-top EDTA tube.
Do not use Serum Separator Tubes.
Time of Collection: Trough, just prior to the next dose.
Record the exact time of specimen collection on the tube or in the computer system.
Physician Office/Draw Specimen Preparation
Let serum specimens clot 30-60 minutes. Refrigerate (2-8°C or 36-46°F) the collection tube within two hours of collection. (Minimum: 2.0 mL blood)
Preparation for Courier Transport
Transport: Collection tube, frozen (-20°C/-4°F or below). (Minimum: 2.0 mL blood)
Rejection Criteria
- Serum Separator (SST) tubes.
- Severely lipemic or hemolyzed specimens.
In-Lab Processing
Let serum specimens clot 30-60 minutes. Centrifuge specimen to separate serum or plasma from cells. Deliver an aliquot of serum or the collection tube immediately to the appropriate testing station.
Storage
Specimen Stability for Testing:
Frozen (-20°C/-4°F or below): 3 months
Specimen Storage in Department Prior to Disposal:
Frozen (-20°C/-4°F or below): 1 month
Laboratory
Royal Oak Toxicology Laboratory
Performed
Monday, Thursday.
Results available the same day as testing performed (1-4 days).
Reference Range
Trough: 1.5-5 mcg/mL
Test Methodology
Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS).
This test was developed, and its performance characteristics determined by Beaumont Health. It has not been cleared or approved by the FDA. The Laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes and should not be regarded as investigational or for research.
Interpretation
Mycophenolic Acid is the active metabolite produced after administration of Mycophenolate Mofetil or Myfortic™. Mycophenolic Acid is an inosine monophosphate dehydrogenase (IMPDH) inhibitor and blocks de novo guanosine nucleotide synthesis ultimately preventing proliferation of T-and B-lymphocytes producing a diminished immune response. It has replaced Azathioprine in many protocols involving immune suppression in transplantation medicine. Mycophenolic Acid concentrations tend to be decreased with co-administration of Cyclosporine A. Mycophenolic Acid undergoes variable enterohepatic recirculation, which may be disrupted by antibiotics, cholestyramine and antacids also causing decreased MPA serum concentrations. Mycophenolic Acid is extensively bound to plasma proteins and interactions known to disrupt plasma protein binding may increase MPA clearance, such as renal impairment, nephritis, liver disease, hypoalbuminemia, and co-administration with Valproic Acid, Acetylsalicylic Acid or other competitive binding inhibitors.
CPT Codes
80180
LOINC: 55806-4
Contacts
Toxicology Laboratory – RO
248-551-8058
Name: Toxicology Laboratory – RO
Location:
Phone: 248-551-8058
Last Updated
11/6/2024
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.